Inventiva Extends Cash Runway to Mid-2027 on $172.5M U.S. Offering
Event summary
- Inventiva reported €4.5M in 2025 revenues, down from €9.2M in 2024, driven by lower licensing revenues from CTTQ.
- Completed a $172.5M U.S. public offering in November 2025, boosting cash reserves to €99.3M and €131.6M in short-term deposits.
- Cash runway extended to mid-Q1 2027, with potential to reach mid-Q3 2027 if Tranche 3 warrants are fully exercised.
- Sold odiparcil rights to Biossil for $600K upfront, with up to $90M in potential milestone payments and royalties.
- NATiV3 Phase 3 trial topline results expected in Q4 2026, delayed from prior expectations.
The big picture
Inventiva's strategic focus on lanifibranor for MASH is underscored by its recent fundraising and asset sale, positioning the company to navigate the cash-intensive Phase 3 trial period. The delay in topline results reflects the careful sequencing of clinical milestones, but the extended cash runway provides a buffer for potential setbacks. The biopharmaceutical sector's competitive landscape for MASH treatments will be a key factor in Inventiva's long-term success.
What we're watching
- Clinical Trial Timing
- Whether the delayed NATiV3 topline results in Q4 2026 will impact regulatory approval timelines for lanifibranor.
- Cash Burn Management
- How Inventiva will manage its cash burn rate to extend its runway beyond mid-2027, especially if Tranche 3 warrants are not exercised.
- Commercialization Readiness
- The pace at which Inventiva can prepare for potential commercialization of lanifibranor, given the increased pre-commercialization investments.